Replies to post #156565 on Biotech Values

[oc631]

I don’t think GILD will include genotype-3 in the Sofusbuvir/ribavirin NDA submission if they can’t do better than the 56% SVR seen in FISSION.

If GILD pursues approval in both genotypes do you agree the FDA would request separate filings due to the large disparity in SVR rates?